


For Internal Use Only		Submit 1 Original	OMB Approval No.:								
Sec File No. 91 -		and 9 Copies	Expires:								
Estimated average burden hours per response: 2.00											
<div style="float: left; width: 20%;">91-1618</div> <div style="float: right; width: 20%; text-align: right;">             SECURITIES AND EXCHANGE COMMISSION  <b>RECEIVED</b>              APR 17 2007           </div> <div style="clear: both;"></div> <p>UNITED STATES  SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549  FORM 19b-4(e)</p>											
<b>Information Required of a Self-Regulatory Organization Listing and Trading a New  Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934</b>											
<b>READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM</b>											
<b>Part I</b>		<b>Initial Listing Report</b>									
1. Name of Self-Regulatory Organization Listing New Derivative Securities Product: NYSE Arca, Inc.											
2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.): Open-end Management Investment Company											
3. Class of New Derivative Securities Product: Investment Company Units											
4. Name of Underlying Instrument: HealthShares <sup>TM</sup> Cancer Index											
5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based: Narrow-Based											
6. Ticker Symbol(s) of New Derivative Securities Product: HHK											
7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades: New York Stock Exchange, Nasdaq Stock Market, Euronext Paris											
8. Settlement Methodology of New Derivative Securities Product: Regular way trades settle on T+3/Book entry only held in DTC.											
9. Position Limits of New Derivative Securities Product (if applicable): Not applicable.											
<b>Part II</b>		<b>Execution</b>									
The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.											
Name of Official Responsible for Form: Mary Yeager											
Title: Corporate Secretary											
Telephone Number: (212) 656-2062											
Manual Signature of Official Responsible for Form: 											
Date: April 17, 2007											
		<div style="text-align: right;"> <b>PROCESSED</b>  <b>MAY 08 2007</b>  <b>THOMSON</b>  <b>FINANCIAL</b> </div>									
SEC 2449 (1/99)		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Act</td> <td>Securities Exchange Act of 1934</td> </tr> <tr> <td>Section</td> <td>19b-4</td> </tr> <tr> <td>Rule</td> <td>19b-4(e)</td> </tr> <tr> <td>Public Availability:</td> <td>APR 18 2007</td> </tr> </table>		Act	Securities Exchange Act of 1934	Section	19b-4	Rule	19b-4(e)	Public Availability:	APR 18 2007
Act	Securities Exchange Act of 1934										
Section	19b-4										
Rule	19b-4(e)										
Public Availability:	APR 18 2007										

END